ArticleAmerican journal of preventive cardiology2026
Inspecting the association between metabolic obese phenotypes and heart failure subtypes risk.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation.International journal of molecular sciences · 2026Review
- AJPC 2025 in review: A year of growth & clearer mandate for actionable prevention.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Obesity and metabolic unhealth don't always co-exist. The relation between phenotypes derived from metabolic obese status and heart failure (HF) subtypes categorized by left ventricular ejection fraction (LVEF) is unclear. We aimed to investigate the association between metabolic obese phenotypes and future HF subtypes risk. Objectives: A total of 9791 participants from the ARIC study were classified into phenotypes based on obese and metabolic status: metabolically healthy non-obesity (MHNO), metabolically healthy obesity (MHO), metabolically unhealthy non-obesity (MUNO) and metabolically unhealthy obesity (MUO). Methods: Cox regression models were applied to explore the relationship between metabolic obese phenotypes and risk of HF with preserved ejection fraction (HFpEF, LVEF ≥ 50 %) and HF with reduced or mid-range ejection fraction (HFrEF/HFmrEF, LVEF < 50 %) in total population and subgroups. Associations between phenotypes transition over time and HF subtypes risk were further analyzed. Results: Compared with MHNO participants, HFpEF risk was increased in MHO (hazard ratio and 95 % confidence interval, 1.77 [1.39-2.26]), MUNO (1.59 [1.27-1.99]) and MUO (2.77 [2.25-3.40]), while HFrEF/HFmrEF risk were higher in MUNO (1.61 [1.27-2.04]) and MUO (2.19 [1.74-2.75]) participants. Subgroup analyses revealed that the associations between metabolic obese phenotypes and HF subtypes risk were more predominant in participants < 55 years old and female. Persistent MHO, MUNO or MUO were associated with increased HFpEF risk and almost any transition to MUO resulted in increased risk of all HF subtypes. Conclusions: MUNO and MUO were associated with all HF subtypes risk, while MHO was only associated with future HFpEF rather than HFrEF/HFmrEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.